[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment",
    "summary": "Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for indolent non-Hodgkin lymphoma, which was a significant recent event. During the last quarter, the company's stock rose by 8%, amid a backdrop of several key events and broader market trends. Positive results from the Phase 3 POETYK PsA-2 trial for Sotyktu and a substantial share buyback program may have bolstered investor confidence. Additionally, a quarterly dividend...",
    "url": "https://finnhub.io/api/news?id=fb4d2d5f018420cf15acd33d948d09364e9c18145efdbf27e8cadfeecf7d3d6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741973244,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment",
      "id": 133185673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for indolent non-Hodgkin lymphoma, which was a significant recent event. During the last quarter, the company's stock rose by 8%, amid a backdrop of several key events and broader market trends. Positive results from the Phase 3 POETYK PsA-2 trial for Sotyktu and a substantial share buyback program may have bolstered investor confidence. Additionally, a quarterly dividend...",
      "url": "https://finnhub.io/api/news?id=fb4d2d5f018420cf15acd33d948d09364e9c18145efdbf27e8cadfeecf7d3d6f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=ed236530f57e2c3b922afd78311c4a486ebb04af01ec80ee3ded31c289a23acb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741970160,
      "headline": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
      "id": 133220596,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=ed236530f57e2c3b922afd78311c4a486ebb04af01ec80ee3ded31c289a23acb"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma",
    "summary": "PRINCETON, N.J., March 14, 2025--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma",
    "url": "https://finnhub.io/api/news?id=852b8b11e23e53c3a33dc3b66a8225b54f84dc41712e97b5b6b8691ada834ea9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741949940,
      "headline": "Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma",
      "id": 133185674,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., March 14, 2025--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma",
      "url": "https://finnhub.io/api/news?id=852b8b11e23e53c3a33dc3b66a8225b54f84dc41712e97b5b6b8691ada834ea9"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.",
    "summary": "Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving interest.",
    "url": "https://finnhub.io/api/news?id=647713b5d7a0f754f1eb422329ff7d6f6b53fbeb68dfd1d173d7250004069c1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741944600,
      "headline": "Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.",
      "id": 133184431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving interest.",
      "url": "https://finnhub.io/api/news?id=647713b5d7a0f754f1eb422329ff7d6f6b53fbeb68dfd1d173d7250004069c1b"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gets Expanded European Approval for Breyanzi",
    "summary": "By Colin Kellaher Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma. The Princeton, N.J., biopharmaceutical...",
    "url": "https://finnhub.io/api/news?id=f46348bdfafbf083acf6cade7907cd8158b1fda5180037386a67cf6524e72058",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741937547,
      "headline": "Bristol Myers Gets Expanded European Approval for Breyanzi",
      "id": 133168133,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma. The Princeton, N.J., biopharmaceutical...",
      "url": "https://finnhub.io/api/news?id=f46348bdfafbf083acf6cade7907cd8158b1fda5180037386a67cf6524e72058"
    }
  }
]